title: Preparation of DOX/BSANP and its antitumor effect on bel-7404 liver cancer cells in vitro and in vivo.
abstract: This paper aimed to investigate the preparation of doxorubicin-loaded bovine serum albumin nanoparticles (DOX/BSANP) and their effect on killing liver cancer cells in vitro and in vivo. DOX/BSANP was prepared using a desolvation-chemical crosslinking method. Their morphology and particle size were observed using transmission electron microscopy (TEM). The envelopment, drug-loading rates and slow-release characteristics were determined spectrophotometrically. Their ability to kill liver cancer cells in vitro was determined using the methyl thiazolyl tetrazolium (MTT) assay and flow cytometry (FCM). The tumor-suppressing effect of the nanoparticles in experimental animals in vivo was also evaluated. Under TEM, DOX/BSANP appeared spherical and was distributed uniformly, with a diameter of about 120 nm and hydrated particle size of 170 nm determined by dynamic light diffraction. The envelopment rate was 82% and the drug-loading rate was 11.2%. The in vitro drug-release experiment showed that about 50% of the drug in drug-loaded nanoparticles was released continuously and slowly for 7 days. The MTT assay showed that DOX/BSANP significantly inhibited cell proliferation, while FCM showed that it induced tumor cell apoptosis. The in vivo tumor suppression test showed that the therapeutic effect of drug-loaded nanoparticles was superior to that of DOX alone.
authors.affiliation: Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Medical School, Southeast University, No. 87, Dingjiaqiao Road, Nanjing, 210009, Jiangsu Province, China.
authors.forename: Feng-qin
authors.initials: FQ
authors.lastname: Miao
authors.forename: Yan-li
authors.initials: YL
authors.lastname: An
authors.forename: Rui
authors.initials: R
authors.lastname: Yang
authors.forename: Qiu-sha
authors.initials: QS
authors.lastname: Tang
authors.forename: Jian-qiong
authors.initials: JQ
authors.lastname: Zhang
mesh_terms: D000418:Albumins / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis; D002417:Cattle; D045744:Cell Line, Tumor; D003432:Cross-Linking Reagents / Q000737:chemistry; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers / Q000737:chemistry; D005434:Flow Cytometry; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008027:Light; D016014:Linear Models; D008113:Liver Neoplasms / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles / Q000737:chemistry*; D009368:Neoplasm Transplantation; D010316:Particle Size; D012710:Serum Albumin, Bovine / Q000737:chemistry*; D013053:Spectrophotometry; D013696:Temperature; D013997:Time Factors
chemical_list: D000418:Albumins; D000970:Antineoplastic Agents; D003432:Cross-Linking Reagents; D004337:Drug Carriers; D012710:Serum Albumin, Bovine; D004317:Doxorubicin
keywords: DOX; albumin nanoparticles; desolvation-chemical crosslinking; liver cancer